当前位置: 首页 >> 检索结果
共有 3 条符合本次的查询结果, 用时 2.2203798 秒

1. Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies.

作者: .; .
来源: Cell. 2025年188卷3期640-652.e9页
In a genome-wide association study (GWAS) meta-analysis of 688,808 individuals with major depression (MD) and 4,364,225 controls from 29 countries across diverse and admixed ancestries, we identify 697 associations at 635 loci, 293 of which are novel. Using fine-mapping and functional tools, we find 308 high-confidence gene associations and enrichment of postsynaptic density and receptor clustering. A neural cell-type enrichment analysis utilizing single-cell data implicates excitatory, inhibitory, and medium spiny neurons and the involvement of amygdala neurons in both mouse and human single-cell analyses. The associations are enriched for antidepressant targets and provide potential repurposing opportunities. Polygenic scores trained using European or multi-ancestry data predicted MD status across all ancestries, explaining up to 5.8% of MD liability variance in Europeans. These findings advance our global understanding of MD and reveal biological targets that may be used to target and develop pharmacotherapies addressing the unmet need for effective treatment.

2. By their powers combined, global initiative joins forces for genomic research.

作者: Genevieve L Wojcik.
来源: Cell. 2022年185卷23期4256-4258页
Genome-wide association studies (GWASs) can require immense sample sizes to identify variants associated with human health across the frequency spectrum. As the Global Biobank Meta-analysis Initiative (GBMI), Zhou et al. describe a collaborative network across 23 biobanks and 2.2 million participants to address challenges of underrepresentation of diversity in genomic research.

3. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.

作者: Kevin Litchfield.;James L Reading.;Clare Puttick.;Krupa Thakkar.;Chris Abbosh.;Robert Bentham.;Thomas B K Watkins.;Rachel Rosenthal.;Dhruva Biswas.;Andrew Rowan.;Emilia Lim.;Maise Al Bakir.;Virginia Turati.;José Afonso Guerra-Assunção.;Lucia Conde.;Andrew J S Furness.;Sunil Kumar Saini.;Sine R Hadrup.;Javier Herrero.;Se-Hoon Lee.;Peter Van Loo.;Tariq Enver.;James Larkin.;Matthew D Hellmann.;Samra Turajlic.;Sergio A Quezada.;Nicholas McGranahan.;Charles Swanton.
来源: Cell. 2021年184卷3期596-614.e14页
Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features underpinning CPI sensitization. Here, we collated whole-exome and transcriptomic data for >1,000 CPI-treated patients across seven tumor types, utilizing standardized bioinformatics workflows and clinical outcome criteria to validate multivariable predictors of CPI sensitization. Clonal tumor mutation burden (TMB) was the strongest predictor of CPI response, followed by total TMB and CXCL9 expression. Subclonal TMB, somatic copy alteration burden, and histocompatibility leukocyte antigen (HLA) evolutionary divergence failed to attain pan-cancer significance. Dinucleotide variants were identified as a source of immunogenic epitopes associated with radical amino acid substitutions and enhanced peptide hydrophobicity/immunogenicity. Copy-number analysis revealed two additional determinants of CPI outcome supported by prior functional evidence: 9q34 (TRAF2) loss associated with response and CCND1 amplification associated with resistance. Finally, single-cell RNA sequencing (RNA-seq) of clonal neoantigen-reactive CD8 tumor-infiltrating lymphocytes (TILs), combined with bulk RNA-seq analysis of CPI-responding tumors, identified CCR5 and CXCL13 as T-cell-intrinsic markers of CPI sensitivity.
共有 3 条符合本次的查询结果, 用时 2.2203798 秒